IDH1/2 Mutation and MGMT Promoter Methylation - The Relevant Survival Predictors in Czech Patients With Brain Gliomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F16%3AN0000008" target="_blank" >RIV/26475821:_____/16:N0000008 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/16:10332504 RIV/61383082:_____/16:00000251

Výsledek na webu

<a href="http://fb.cuni.cz/file/5820/fb2016a0024.pdf" target="_blank" >http://fb.cuni.cz/file/5820/fb2016a0024.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

IDH1/2 Mutation and MGMT Promoter Methylation - The Relevant Survival Predictors in Czech Patients With Brain Gliomas

Popis výsledku v původním jazyce

Gliomas are a heterogeneous group of tumours varying in prognosis, treatment approach, and overall survival. Recently, novel markers have been identified which are linked to patient prognosis and therapeutic response. Especially the mutation of the enzyme isocitrate dehydrogenase 1 or 2 (IDH1/2) gene and the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status seem to be the most important predictors of survival. From 2012 to 2015, 94 Czech patients with primary brain tumours were enrolled into the study. The IDH1/2 mutation was detected by denaturing capillary electrophores.The methylation status of the MGMT gene and other 46 genes was revealed by MS-MLPA. In all 94 patients, the clinical data were correlated with molecular markers by Kaplan-Meier analyses and Cox regression model.

Název v anglickém jazyce

IDH1/2 Mutation and MGMT Promoter Methylation - The Relevant Survival Predictors in Czech Patients With Brain Gliomas

Popis výsledku anglicky

Gliomas are a heterogeneous group of tumours varying in prognosis, treatment approach, and overall survival. Recently, novel markers have been identified which are linked to patient prognosis and therapeutic response. Especially the mutation of the enzyme isocitrate dehydrogenase 1 or 2 (IDH1/2) gene and the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status seem to be the most important predictors of survival. From 2012 to 2015, 94 Czech patients with primary brain tumours were enrolled into the study. The IDH1/2 mutation was detected by denaturing capillary electrophores.The methylation status of the MGMT gene and other 46 genes was revealed by MS-MLPA. In all 94 patients, the clinical data were correlated with molecular markers by Kaplan-Meier analyses and Cox regression model.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT14253" target="_blank" >NT14253: Epigenetické markery ovlivňující chování mozkových nádorů</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Folia Biologica (Praha)

ISSN

0015-5500

e-ISSN

—

Svazek periodika

62

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

9

Strana od-do

194-202

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—